Michael J. Detke - Jul 6, 2021 Form 4 Insider Report for Cortexyme, Inc. (QNCX)

Role: Chief Medical Officer
Signature: /s/ Caryn Gordon McDowell, Attorney-in-Fact for Michael J. Detke, M.D.
Stock symbol: QNCX
Transactions as of: Jul 6, 2021
Transactions value $: -$3,081,272
Form type: 4
Date filed: 7/7/2021, 08:38 PM
Next filing: Aug 12, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	QNCX	Common Stock	Options Exercise	$28.1K	+12.6K	+44.58%	$2.23	40.9K	Jul 6, 2021	Direct
transaction	QNCX	Common Stock	Sale	-$1.73M	-32.3K	-79.08%	$53.43^*	8.55K	Jul 6, 2021	Direct	F1, F2
transaction	QNCX	Common Stock	Sale	-$445K	-8.26K	-96.63%	$53.91^*	288	Jul 6, 2021	Direct	F1, F3
transaction	QNCX	Common Stock	Sale	-$15.8K	-288	-100%	$55.01^*	0	Jul 6, 2021	Direct	F1
transaction	QNCX	Common Stock	Options Exercise	$38.8K	+17.4K		$2.23	17.4K	Jul 7, 2021	Direct
transaction	QNCX	Common Stock	Sale	-$209K	-3.93K	-22.61%	$53.24^*	13.5K	Jul 7, 2021	Direct	F1, F4
transaction	QNCX	Common Stock	Sale	-$89.6K	-1.65K	-12.24%	$54.37^*	11.8K	Jul 7, 2021	Direct	F1, F5
transaction	QNCX	Common Stock	Sale	-$241K	-4.35K	-36.83%	$55.38^*	7.47K	Jul 7, 2021	Direct	F1, F6
transaction	QNCX	Common Stock	Sale	-$391K	-6.94K	-92.99%	$56.27^*	523	Jul 7, 2021	Direct	F1, F7
transaction	QNCX	Common Stock	Sale	-$29.8K	-523	-100%	$56.99^*	0	Jul 7, 2021	Direct	F1, F8

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	QNCX	Stock Option (right to buy)	Options Exercise	$0	-12.6K	-9.52%	$0.00	120K	Jul 6, 2021	Common Stock	12.6K	$2.23	Direct	F9
transaction	QNCX	Stock Option (right to buy)	Options Exercise	$0	-17.4K	-14.53%	$0.00	102K	Jul 7, 2021	Common Stock	17.4K	$2.23	Direct	F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 19, 2021.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.69 to $53.68, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.71 to $54.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.745 to $53.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.75 to $54.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F6	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.79 to $55.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F7	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.80 to $56.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F8	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.81 to $57.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F9	The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022.